TP53 and neoplasm: Preliminary data suggest that these agents can also elicit synthetic lethality in the presence of mutations in other tumor suppressor, such as TP53 and PTEN, which are mutated in 37% and 3% of all BCs, respectively, and represented 11.8% and 5.4% of mutations in our sample.30, 31